Immunoglobulin G fragment C receptor polymorphisms and response to trastuzumab-based treatment in patients with HER-2/neu-positive metastatic breast cancer

被引：0
|
作者：
Musolino, A. [1 ]
Naldi, N. [1 ]
Bortesi, B. [1 ]
Capelletti, M. [1 ]
Pezzuolo, D. [1 ]
Michiara, M. [1 ]
Missale, G. [1 ]
Laccabue, D. [1 ]
Zerbini, A. [1 ]
Camisa, R. [1 ]
Ardizzoni, A. [1 ]
机构：
[1] Univ Hosp Parma, Parma, Italy
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2007年 / 103卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：119 / 120
页数：2
相关论文
共 50 条
  • [31] Estimating Recurrences Prevented From Using Trastuzumab in HER-2/neu-Positive Adjuvant Breast Cancer in the United States
    Danese, Mark D.
    Lalla, Deepa
    Brammer, Melissa
    Doan, Quan
    Knopf, Kevin
    CANCER, 2010, 116 (24) : 5575 - 5583
  • [32] Dataset used in the economic evaluation trastuzumab-based regimens for HER-2 positive metastatic breast cancer patients in the Taiwanese healthcare setting
    Diaby, Vakaramoko
    Wang, Ching-Yu
    Alqhtani, Hussain
    van Boemmel-Wegmann, Sascha
    Ali, Askal Ayalew
    Balkrishnan, Rajesh
    Ko, Yu
    Palacio, Sofia
    Lopes, Gilberto de Lima
    DATA IN BRIEF, 2020, 29
  • [33] Cost Utility of Sequential Adjuvant Trastuzumab for HER2/Neu-Positive Breast Cancer
    Reed, Shelby D.
    Schulman, Kevin A.
    VALUE IN HEALTH, 2009, 12 (05) : 637 - 640
  • [34] The real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu-positive early breast cancer in Taiwan
    Lang, Hui-Chu
    Chen, Hsiao-Wei
    Chiou, Tzeon-Jye
    Chan, Agnes L. F.
    JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (10) : 923 - 927
  • [35] Trastuzumab use beyond progression on previous trastuzumab treatment in HER-2 positive metastatic breast cancer
    Hutka, Margaret M.
    Kolosza, Zofia
    Utracka-Hutka, Beata
    ANNALS OF ONCOLOGY, 2007, 18 : 163 - 163
  • [36] HER-2 positive inflammatory breast cancer: high pathological response rate with trastuzumab-based neoadjuvant therapy.
    Dawood, S.
    Gonzales-Angulo, A. M.
    Broglio, k
    Gong, Y.
    Resetkova, E.
    Yang, W. T.
    Barnett, C. M.
    Islam, R.
    Ueno, N. T.
    Hortobagyi, G. N.
    Cristofanilli, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S186 - S186
  • [37] Detection of HER-2/neu-positive circulating epithelial cells in prostate cancer patients
    Ady, N
    Morat, L
    Fizazi, K
    Soria, JC
    Mathieu, MC
    Prapotnich, D
    Sabatier, L
    Chauveinc, L
    BRITISH JOURNAL OF CANCER, 2004, 90 (02) : 443 - 448
  • [38] Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC)
    Giuliani, Rosa
    Durbecq, Virginie
    Di Leo, Angelo
    Paesmans, Marianne
    Larsimont, Denis
    Leroy, Jean-Yves
    Borms, Marleen
    Vindeuoghel, Anita
    Jerusalem, Guy
    D'Hondt, Veronique
    Dirix, Luc
    Canon, Jean-Luc
    Richard, Vincent
    Cocquyt, Veronique
    Majois, Francoise
    Reginster, Michel
    Demol, Jan
    Kains, Jean-Pierre
    Delree, Paul
    Keppens, Carine
    Sotiriou, Christos
    Piccart, Martine J.
    Cardoso, Fatima
    EUROPEAN JOURNAL OF CANCER, 2007, 43 (04) : 725 - 735
  • [39] Immunoglobulin G fragment C gamma receptor (FcGR) polymorphisms and efficacy of single-agent trastuzumab in patients treated with metastatic breast cancer
    Shimizu, C.
    Tamura, K.
    Koizumi, F.
    Aogi, K.
    Kinoshita, T.
    Fujiwara, Y.
    CANCER RESEARCH, 2009, 69 (02) : 368S - 370S
  • [40] Trastuzumab-Based Neoadjuvant Therapy in Patients With HER2-Positive Breast Cancer
    Chang, Helena R.
    CANCER, 2010, 116 (12) : 2856 - 2867
12345